Here are the 424B prospectus supplements from BlossomHill Therapeutics, Inc. (BLSM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BLSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLSM filings page.
BlossomHill Therapeutics, Inc. (BLSM), a clinical-stage oncology-focused biopharmaceutical company, is conducting an initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share, for gross proceeds of $150.0 million before underwriting discounts. Underwriters have a 30‑day option to purchase up to 1,406,250 additional shares. Net proceeds to BlossomHill before expenses are expected to be $139.5 million, or $14.88 per share.
The company develops small‑molecule cancer therapies, led by BH‑30643, an OMNI‑EGFR inhibitor for EGFR‑mutant non‑small cell lung cancer in a Phase 1/2 trial, BH‑30236, a CLK inhibitor in a Phase 1 trial for relapsed/refractory AML and higher‑risk MDS, and BH‑501284, a preclinical pan‑KRAS inhibitor with IND filing planned in 2027. BlossomHill reported research and development expenses of $56.1 million and a net loss of $60.6 million in 2025, with an accumulated deficit of $156.0 million as of March 31, 2026.
Cash and cash equivalents were $116.0 million as of March 31, 2026, rising to a pro forma as‑adjusted $253.6 million after giving effect to the offering. The company’s auditors included a going concern explanatory paragraph, and BlossomHill states that even with IPO proceeds it will require substantial additional capital to complete development and potential commercialization of its pipeline. The common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “BLSM.”